Accurate diagnosis forms the foundation of effective cancer care. A fundamental aspect of my research is to develop effective diagnostics to guide appropriate therapies for gynaecological cancers. We were one of the original advocates of studying and treating various histological subtypes of ovarian cancer as distinct diseases, both in research and clinically. Using this research, my laboratory discovered key mutations driving several ovarian cancers and rapidly translated these findings into clinical diagnostics. In collaboration with the Proteomics Platform at the BC Cancer, we are using a proteomic-based strategy to develop and identify highly specific immunohistochemical markers to supplement standard pathology which can be more readily translated into global practice changes as compared to nucleic-acid based approaches. In particular, we are interested in studying the protein profiles to identify antibody targets that can discriminate between and accurately diagnose look-alike tumours, which will have an immediate positive impact on patient treatment.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.